78results about "Antigen-carrier link" patented technology

The invention relates to the technical field of biology, in particular to a polyvalent pneumococcal polysaccharide-protein conjugate composition for preventing pneumococcal infection and VZV infection as well as a preparation method and application of the polyvalent pneumococcal polysaccharide-protein conjugate composition. According to the composition containing the multivalent pneumococcal polysaccharide-protein conjugate, an adopted carrier protein is a VZV recombinant protein with immunogenicity; the pneumococcal polysaccharide is connected with the VZV recombinant protein through a covalent bond; the VZV recombinant protein is selected from gE protein, and the amino acid sequence of the VZV recombinant protein is shown as SEQ ID NO: 3 or SEQ ID NO: 4. Aiming at the main epidemic condition of specific serotype pneumococcus in China, serotype combinations of 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F are creatively selected, so that the composition containing the multivalent pneumococcus polysaccharide-protein conjugate, which is designed aiming at the epidemic condition of the specific serotype pneumococcus in China, is developed.

Methods of producing bioconjugates of O-antigen polysaccharides covalently linked to a carrier protein using recombinant host cells are provided. The recombinant host cells used in the methods described herein encode a particular oligosaccharyl transferase enzyme depending on the O-antigen polysaccharide bioconjugate to be produced. The oligosaccharyl transferase enzymes can be PglB oligosaccharyl transferase or variants thereof. Also provided are compositions containing the bioconjugates, and methods of using the bioconjugates and compositions described herein to vaccinate a subject against extra-intestinal pathogenic E. coli. (ExPEC).

This invention relates to the field of biotechnology, specifically to a composition containing a multivalent pneumococcal polysaccharide-protein conjugate for the prevention of pneumococcal infection and VZV infection, its preparation method, and its application. The composition of this invention, comprising a multivalent pneumococcal polysaccharide-protein conjugate, uses an immunogenic VZV recombinant protein as the carrier protein; the pneumococcal polysaccharide is covalently linked to the VZV recombinant protein; the VZV recombinant protein is selected from gE protein, and its amino acid sequence is shown in SEQ ID NO: 3 or SEQ ID NO: 4. This invention addresses the prevalence of serotypes of pneumococcus unique to my country by creatively selecting serotype combinations of 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. This results in a composition containing polyvalent pneumococcal polysaccharide-protein conjugates designed specifically for the prevalence of these serotypes in my country.

The present invention relates to a ferritin nanocage fused with PD-L1-binding peptide 1 and a use thereof as an anticancer immunotherapy agent. Prepared in the present invention were nanocages that are formed by fusing a human ferritin monomer with a peptide 1 (PD-L1pep1: CLQKTPKQC) binding to the immune checkpoint receptor PD-L1 overexpressed in many cancers such as breast cancer, colorectal cancer, renal cancer, glioblastoma, etc. and which display 24 Pd-L1prep1. The nanocages of the present invention effectively target colorectal cancer tissues to exhibit an anticancer effect. When loading the anticancer agent doxorubicin thereinto, the nanocages showed higher anticancer effects than the same dose of PD-L1 antibody. Accordingly, the nanocages are expected as a next-generation drug that surmounts the limitation of immune checkpoint blocking therapy using antibodies.

The present disclosure provides recombinantly manufactured fusion proteins comprising a SARS-CoV-2 Receptor Binding Domain (SARS-CoV-2-RBD) fragment or an analog thereof linked to a human Fc fragment for use in relation to the 2019 Novel Coronavirus (COVID-19). Embodiments include the administration of the fusion proteins to patients that have recovered from COVID-19 as a booster vaccination, to antibody naïve patients to produce antibodies to the SARS-CoV-2 virus to enable the patients to become convalescent plasma donors, to patients who have been infected by the SARS-CoV-2 virus and have contracted COVID-19 in order to limit the scope of the infection and ameliorate the disease, and as a prophylactic COVID-19 vaccine. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

The present invention relates to a polyvalent pneumococcal polysaccharide protein conjugate and immunogenicity thereof, and specifically provides an immunogenic composition containing capsular polysaccharides of streptococcus pneumoniae from different serotypes, and a carrier, the serotypes at least comprising 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F and 33F. The immunogenic composition can improve the immunogenicity of polysaccharides of different serotypes, and may prevent invasive infection caused by pneumococci of various different serotypes.

The present application relates to a dendritic cell-targeted allergen nanovaccine. The present application discloses a nanovaccine which is internally wrapped with an allergen and externally coupled with a dendritic cell targeting molecule. The present application also provides a preparation method and use of the nanovaccine. The nanovaccine can be specifically taken up by dendritic cells, and induce cell tolerance, and is used for specific immunotherapy of allergic diseases.

To provide safe and effective means to induce tolerance to cedar pollen antigens (e.g., CRYJ1 and CRYJ2) in subjects that suffer from Japanese cedar pollinosis, or in subjects at risk for developing Japanese cedar pollinosis, taking account of the substantial prevalence of the disease, particularly in Japan and neighboring countries, and the likelihood of antibody cross-reactivity between conifer pollens.SOLUTION: The present invention provides compositions comprising particles with a negative zeta potential that encapsulate one or more epitopes associated with Japanese cedar pollen. Methods of inducing immunological tolerance to Japanese cedar pollen by administering the particles are also provided.SELECTED DRAWING: Figure 1

To provide a manufacturing condition related to conjugation of capsular polysaccharide from Streptococcus pneumoniae to carrier protein.SOLUTION: A method for producing a polysaccharide-protein conjugate includes allowing polysaccharide in first solution to react with protein in second solution to from third solution, and performing polysaccharide-protein conjugation reaction in the third solution to create a polysaccharide-protein conjugate, where the third solution contains at least 1 mM of salt. It is preferable that the salt be sodium salt, potassium salt, lithium salt, magnesium salt or calcium salt. A polyvalent pneumococcal vaccine can contain the polysaccharide-protein conjugate produced by using a process of the present invention.SELECTED DRAWING: Figure 1

Immunogens include an immunogenic carrier and an antigenic apoptosis-related spot-like protein containing a caspase activation and recruitment domain (ASC) peptide linked to the immunogenic carrier. In one or more embodiments, the immunogenic vector is a Q [beta] virus-like particle (VLP). The immunogen may be formulated as a composition useful in the treatment of inflammatory medical conditions.

Technologies for the prevention and / or treatment of pneumococcal infections.

The present invention provides phagocytic particles for treating or preventing cancer in a subject, wherein the phagocytic particle comprises a core and a neoantigen construct tightly associated with the core, and wherein the neoantigen construct comprises a neoepitope peptide having an amino acid sequence corresponding to the amino acid sequence of a portion of a protein or peptide known or suspected to be expressed by a cancer cell in the subject, wherein the portion of the protein or peptide has at least one somatically mutated amino acid. The present invention also relates to an injectable pharmaceutical composition for treating or preventing cancer.

The present disclosure provides methods of preparing heteroaryl-containing compounds, wherein an azide-alkyne cycloaddition is accelerated in the presence of lauryldimethylamine oxide (LDAO). The present disclosure further provides conjugates of polypeptides and antigens prepared using such methods.

The invention relates to a preparation method of a babesiella bovis vaccine, belongs to the technical field of vaccines, and particularly relates to a combined vaccine based on silver nanoparticles (AgNPs) and theileria bovis antigen, the vaccine comprises 10-50nm AgNPs, the surface of the AgNPs is modified with carboxyl, amino or PEG, and the AgNPs are used for covalently coupling RAP-1 protein or immunogenic fragments thereof and MSA-2 protein or B cell epitope peptide thereof, the RAP-1 protein comprises an amino acid sequence (nucleotide sequence is as shown in SEQ ID NO: 1), the MSA-2 protein comprises an amino acid sequence (nucleotide sequence is as shown in SEQ ID NO: 2), and the preparation method comprises the following steps: carrier construction, recombinant expression, protein purification and AgNPs coupling to form a silver nanoparticle antigen compound, and the silver nanoparticle antigen compound is coated with chitosan to prolong the in-vivo half-life period.

To provide an improved process related to the conjugation of capsular polysaccharides from Streptococcus pneumoniae (S. pneumoniae) serotype 35B to a carrier protein, and a prepared serotype 35B polysaccharide-protein conjugate.SOLUTION: A serotype 35B S. pneumoniae polysaccharide-protein conjugate has a molecular weight of 1,000 kDa to 7,000 kDa. The conjugate comprises a lysine consumption of 3 mol / mol protein to 9 mol / mol protein. A process for making the conjugate comprises activation of the polysaccharide, wherein the activation utilizes periodate in a range of 0.01 to 0.1 moles of periodate per mole of polysaccharide repeating unit.SELECTED DRAWING: Figure 1A

The invention discloses a novel titanium-functionalized whole-tumor vaccine and a preparation method and application thereof.The preparation method comprises the steps that Lewis lung cancer cells are collected, washed and precipitated, normal saline is added for resuspension at the room temperature, TiBALDH is added at the same time, and the mixture is mixed to be uniform to obtain a mixed solution; oscillating and incubating the obtained mixed solution for a period of time, so that Ti in the mixed solution is in full contact with the tumor cells, and the Ti and the tumor cells are combined to form mineralized particles, thereby realizing biomimetic mineralization to obtain mineralized cells; and centrifuging and washing the obtained mineralized cells to obtain the titanium functionalized whole tumor cell vaccine. And finally adding ultrapure water and carrying out low-temperature resuspension preservation. The titanium-functionalized whole tumor cell vaccine prepared by the invention can enhance immunocompetence, stimulate DC maturation and play an immune activation role, can also retain that a complete tumor antigen can induce immune response without tumorigenic risk, and has good safety, so that the titanium-functionalized whole tumor cell vaccine is expected to be applied to tumor immunotherapy and has a relatively wide application prospect.

Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions are described comprising conjugates of E. coli polysaccharide antigen O1, 02, 04, 06, 08, 015, 016, 018, 025, and 075 and further comprising 0153 or 021 or both 0153 and 021 covalently bound to a carrier protein for the prevention of invasive ExPEC disease.

Described herein is a tumor therapeutic composition or tumor vaccine which can be produced by protein transfer of glycosyl-phosphatidylinositol (GPI)-anchored immunostimulatory or costimulatory molecules.

Provided herein are compositions and methods related to CMV gB proteins in which amino acid substitutions have been made to disrupt the postfusion state and / or stabilize the prefusion state.

The present invention relates to a novel vaccine formulation comprising a conjugated Streptococcus pneumoniae capsular saccharide antigen (glycoconjugate), and to the use thereof. The present invention relates to a novel vaccine formulation comprising a conjugated Streptococcus pneumoniae capsular saccharide antigen (glycoconjugate). The vaccine formulations of the present invention would typically include at least one glycoconjugate from Streptococcus pneumoniae serotype in a formulation designed to promote resuspension.

To provide additional pneumococcal vaccine compositions which can provide protection against pneumococcal serotypes not present in currently available vaccines.SOLUTION: The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, where each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein. In some embodiments, at least one polysaccharide protein conjugate is formed by a conjugation reaction comprising an aprotic solvent. In other embodiment, each of the polysaccharide protein conjugates are formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient.SELECTED DRAWING: Figure 1

A method of encapsulating a biomolecule in a silica shell to form a particle, the method comprising: • a) hydrolyzing a mixture of silica precursors, said mixture comprising a functionalized silica precursor comprising a Si-C bond and a non-functionalized silica alkoxide precursor, • b) directly contacting the hydrolyzed precursors with an aqueous solution comprising the biomolecule and • c) encapsulating the biomolecule in a silica shell to form a particle, such that at least a portion of the silica on the interior surface of the silica shell is functionalized and comprises a Si-C bond.

In one aspect, the present disclosure relates to an immunogenic composition comprising conjugated O-polysaccharide molecules derived from E. coli lipopolysaccharides. In one embodiment, the O-polysaccharide molecules are conjugated to streptococcal C5a peptidase (SCP). In some embodiments, the O-polysaccharide molecules are conjugated to SCP using click chemistry.

The invention relates to the technical field of medicine, in particular to an antigen double burst release self-boosting immune vaccine and application thereof.The antigen double burst release self-boosting immune vaccine is characterized in that antigens are loaded inside and outside complex coacervation microcapsules in the vaccine, nanoparticles are prepared through a nanoprecipitation method, the nanoparticles and cell membranes jointly entrap the antigens to form functional nanoparticles, and the functional nanoparticles are used as functional nanoparticles; the preparation method comprises the following steps: coating functionalized nanoparticles by using a micro-fluidic technology and a complex coagulation method to prepare microcapsules, coating the surface of the microcapsules by using dopamine hydrochloride auto-polymerization reaction to form coating microcapsules, and finally blending with the functionalized nanoparticles, thereby dividing the antigen into an inner part and an outer part. After entering a body, the nano-microparticle carrier double burst release vaccine is subjected to antigen double burst release with time lag intervals in different time periods; the prepared vaccine can release antigens firstly, then effectively collect and activate antigen presenting cells, the antigen presenting cells uptake the antigen presenting cells to cause immune response, and the generation of specific antibodies can be effectively induced by two times of antigen release through the time-delay coating, so that a traditional natural immune procedure is simulated.

The present invention relates to new vaccine formulations comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Vaccine formulations of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype in a formulation designed to facilitate resuspension.

The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, the present invention relates to sized Streptococcus pneumoniae serotype 6A capsular polysaccharides, in particular Streptococcus pneumoniae serotype 6A capsular polysaccharides having the average size (e.g. Mw) of the Streptococcus pneumoniae serotype 6A capsular polysaccharide is between 100-1000 kDa, suitably conjugated to a carrier protein.

The present disclosure provides T-cell modulatory antigen-presenting polypeptides, including single-chain antigen-presenting polypeptides and multimeric antigen-presenting polypeptides. The present disclosure provides nucleic acids comprising nucleotide sequences encoding T-cell modulatory antigen-presenting polypeptides of the present disclosure, as well as cells genetically modified with the nucleic acids. A T-cell modulatory antigen-presenting polypeptide of the present disclosure is useful for modulating activity of a T cell. Thus, the present disclosure provides methods of modulating activity of a T cell.

The present invention relates to immunogenic compositions and vaccine compositions comprising the antigens AliA or immunogenic fragments thereof and PnrA and immunogenic fragments thereof from Streptococcus pneumoniae and uses thereof in the treatment and / or prevention of infections by S. pneumoniae.

The application discloses a Gitta virus genetically engineered subunit vaccine and a preparation method and application thereof, and belongs to the technical field of vaccine preparation. The Gitta virus P6E recombinant protein is obtained by using a eukaryotic expression system, and is further loaded on the surface of a nanoparticle skeleton to form a recombinant nanoparticle. The obtained recombinant protein and the recombinant nanoparticle are respectively compounded with an adjuvant to prepare the genetically engineered subunit vaccine. After twice immunization, the vaccines of the two components can significantly induce the host to produce strong humoral immune and cellular immune responses, thereby providing effective protection against GETV infection. The technical scheme of the application provides an important technical basis and application reference for research and optimization of the Gitta virus vaccine.

Chimeric antigen receptor-transduced T cells (CAR-T cells) show significant efficacy on some hematological malignancies. However, the CAR target is limited to a few antigens, which is primarily due to the non-tumor targeted toxicity of CAR-T cells. Although several strategies are proposed to avoid non-tumor targeted toxicity, the majority of which use complex designs including dual gene expression to achieve specificity. In this study, we have shown that switchable CAR immune cells (e.g., CAR-T cells) with tumor-targeting adapters can mitigate non-tumor-targeting toxicity against tumor antigens, due to which conventional CAR immune cells cannot target tumor antigens such as CD40 and CS1. Therefore, the switchable CAR system is a valuable tool for controlling the toxicity of CAR-T cells while keeping the treatment effect so as to realize CAR anti-tumor targeting expansion.